GlassScriptPhysician profile
Shandi Mae Husen
NPI 1518469428
$7,212.01
in general payments reported to CMS, 2019-2025
38 companies · $2,254 in 2025
The $2,254 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,094 · 2022: $1,167 · 2023: $1,045 · 2024: $1,651 · 2025: $2,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,489 · Consulting Fee: $1,283 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,489.26 |
| Consulting Fee | $1,282.50 |
| Education | $178.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,229.59 | 2021-2025 | |
| Dendreon Pharmaceuticals LLC | $939.54 | 2021-2025 | Provenge |
| Janssen Biotech, INC. | $611.65 | 2021-2025 | Erleada, Balversa, Akeega |
| Astellas Pharma US INC | $569.24 | 2021-2025 | Xtandi |
| Janssen Scientific Affairs, LLC | $562.50 | 2024 | |
| Merck Sharp & Dohme LLC | $375.63 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Sumitomo Pharma America, INC. | $347.88 | 2023-2025 | Orgovyx, Gemtesa |
| Teleflex LLC | $312.83 | 2021-2025 | Urolift, Barrigel |
| Myriad Genetic Laboratories, INC. | $289.65 | 2021-2025 | Prolaris, Myrisk |
| Bayer Healthcare Pharmaceuticals INC. | $259.64 | 2021-2025 | |
| Blue Earth Diagnostics | $238.76 | 2021-2024 | |
| Tolmar Pharmaceuticals, INC. | $214.51 | 2021-2022 | |
| Urogen Pharma, INC. | $130.12 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $106.06 | 2024-2025 | |
| Urovant Sciences INC | $101.79 | 2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $89.66 | 2021-2025 | |
| Accord Healthcare, INC. | $77.11 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $76.55 | 2023-2025 | Adstiladrin |
| Abbvie INC. | $68.77 | 2021-2022 | |
| Amgen INC. | $67.55 | 2021-2022 | |
| Telix Pharmaceuticals | $64.24 | 2024-2025 | Illuccix |
| Axonics, INC. | $54.31 | 2023 | Bulkamid |
| Novo Nordisk INC | $46.19 | 2024 | Rivfloza |
| Calyxo, INC. | $44.22 | 2024-2025 | Cvac Aspiration System |
| Coloplast Corp | $40.71 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $39.08 | 2021 | |
| Alnylam Pharmaceuticals INC. | $38.67 | 2024-2025 | Oxlumo, Givlaari |
| Sun Pharmaceutical Industries INC. | $36.55 | 2021-2025 | |
| Pharmaand Gmbh | $30.48 | 2025 | Rubraca |
| Novocure INC. | $23.23 | 2021 | |
| Procept Biorobotics Corporation | $19.86 | 2025 | |
| Novartis Pharmaceuticals Corporation | $17.11 | 2023 | |
| Tolmar, INC. | $17.08 | 2025 | Eligard, Rubraca |
| Verity Pharmaceuticals INC. | $16.31 | 2023 | Trelstar |
| Boston Scientific Corporation | $15.64 | 2023 | Rezum Generator |
| Olympus America INC. | $14.36 | 2025 | Itind System |
| Endo Pharmaceuticals INC. | $13.46 | 2021 | |
| Myovant Sciences INC. | $11.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shandi Husen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.